The Role of α-Cell Dysregulation in Fasting and Postprandial Hyperglycemia in Type 2 Diabetes and Therapeutic Implications
The DOI matches its Crossref record; 313 of the 323 references it cites were found in a registry or an index.
Abstract
The hyperglycemic activity of pancreatic extracts was encountered some 80 yr ago during efforts to optimize methods for the purification of insulin. The hyperglycemic substance was named "glucagon," and it was subsequently determined that glucagon is a 29-amino acid peptide synthesized and released from pancreatic alpha-cells. This article begins with a brief overview of the discovery of glucagon and the contributions that somatostatin and a sensitive and selective assay for pancreatic (vs. gut) glucagon made to understanding the physiological and pathophysiological roles of glucagon. Studies utilizing these tools to establish the function of glucagon in normal nutrient homeostasis and to document a relative glucagon excess in type 2 diabetes mellitus (T2DM) and precursors thereof are then discussed. The evidence that glucagon excess contributes to the development and maintenance of fasting hyperglycemia and that failure to suppress glucagon secretion contributes to postprandial hyperglycemia is then reviewed. Although key human studies are emphasized, salient animal studies highlighting the importance of glucagon in normal and defective glucoregulation are also described. The past eight decades of research in this area have led to development of new therapeutic approaches to treating T2DM that have been shown to, or are expected to, improve glycemic control in patients with T2DM in part by improving alpha-cell function or by blocking glucagon action. Accordingly, this review ends with a discussion of the status and therapeutic potential of glucagon receptor antagonists, alpha-cell selective somatostatin agonists, glucagon-like peptide-1 agonists, and dipeptidyl peptidase-IV inhibitors. Our overall conclusions are that there is considerable evidence that relative hyperglucagonemia contributes to fasting and postprandial hyperglycemia in patients with T2DM, and there are several new and emerging pharmacotherapies that may improve glycemic control in part by ameliorating the hyperglycemic effects of this relative glucagon excess.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“in patients with T2DM elevated plasma glucagon levels have been observed in the fasting state, and defective suppression of glucagon secretion exists in the postprandial state, resulting in elevated plasma glucagon levels (7)”
From Mathematical Model of Glucagon Kinetics for the Assessment of Insulin-Mediated Glucagon Inhibition During an Oral Glucose Tolerance Test (2021) · cites this paper as [7]
In the citing paper
“dysregulated α-cell release of glucagon, manifest as increased fasting glucagon concentrations and a failure to adequately suppress glucagon release following meal ingestion, contributes to the development of hyperglycaemia34.”
From Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future (2014) · cites this paper as [34]
Citations
Cites
Hypothalamic Polypeptide That Inhibits the Secretion of Immunoreactive Pituitary Growth Hormone
Brazeau, P., Vale, W., Burgus, R., Ling, N., Butcher, M., Rivier, J., & Guillemin, R. (1973) · Science · doi:10.1126/science.179.4068.77 · Cited by 3,532
Immunoassay of endogenous plasma insulin in man
Yalow, R. S., & Berson, S. A. (1960) · Journal of Clinical Investigation · doi:10.1172/jci104130 · Cited by 3,041
Pathogenesis of NIDDM. A balanced overview.
DeFronzo, R. A., Bonadonna, R. C., & Ferrannini, E. (1992) · Diabetes Care · doi:10.2337/diacare.15.3.318 · Cited by 2,085
Methods of Hormone Radioimmunoassay
(1978) · Elsevier eBooks · doi:10.1016/b978-0-123-79260-0.x5001-8 · Cited by 2,077
Glucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928
DeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559
(2004) · doi:10.1016/s0092-8674(04)00452-0 · Cited by 1,356
Buse, J. B., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., & for the Exenatide-113 Clinical Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2628 · Cited by 1,346
Zander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297
Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides
Mentlein, R. (1999) · Regulatory Peptides · doi:10.1016/s0167-0115(99)00089-0 · Cited by 1,272
Research works printed but not linked: 9
- 2005, Sandostatin LAR depot (octreotide acetate for injectable suspension).
- 2005, Byetta (exenatide injection)[prescribing information].
- Pratley, 2005, Dipeptidyl peptidase-4 inhibition in type 2 diabetes mellitus., Sci Med, 10, 13
- Villhauer, 2001, DPP-IV inhibition and therapeutic potential., Annu Rep Med Chem, 36, 191
- Balas, J Clin Endocrinol Metab
- Dejager, Horm Metab Res
- Bosi, Diabetes Care
- Rosenstock, Diabetes Obes Metab
- Garber, Diabetes Obes Metab
Cited by
Items 101–200 of 421
Gu, W., Winters, K. A., Motani, A. S., Komorowski, R., Zhang, Y., Liu, Q., Wu, X., Rulifson, I. C., Sivits, G., Graham, M., et al. (2010) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00102.2010 · Cited by 54
Glucagon as a Critical Factor in the Pathology of Diabetes
Edgerton, D. S., & Cherrington, A. D. (2011) · Diabetes · doi:10.2337/db10-1594 · Cited by 47
Degradation of PHLPP2 by KCTD17, via a Glucagon-Dependent Pathway, Promotes Hepatic Steatosis
Kim, K., Ryu, D., Dongiovanni, P., Ozcan, L., Nayak, S., Ueberheide, B., Valenti, L., Auwerx, J., & Pajvani, U. B. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.08.039 · Cited by 51
MafB Is Critical for Glucagon Production and Secretion in Mouse Pancreatic α Cells In Vivo
Katoh, M., Jung, Y., Ugboma, C. M., Shimbo, M., Kuno, A., Basha, W. A. A., Kudo, T., Oishi, H., & Takahashi, S. (2018) · Molecular and Cellular Biology · doi:10.1128/mcb.00504-17 · Cited by 54
Glucagon‐like peptide‐1 receptor agonists for type 2 diabetes: A rational drug development
Ahrén, B. (2019) · Journal of Diabetes Investigation · doi:10.1111/jdi.12911 · Cited by 48
Morgan, E. S., Tai, L.-J., Pham, N. C., Overman, J. K., Watts, L. M., Smith, A., Jung, S. W., Gajdošík, M., Krššák, M., Krebs, M., et al. (2019) · Diabetes Care · doi:10.2337/dc18-1343 · Cited by 50
Tudurí, E., Filiputti, E., Carneiro, E. M., & Quesada, I. (2008) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00641.2007 · Cited by 53
Ramakrishnan, S. K., Zhang, H., Takahashi, S., Centofanti, B., Periyasamy, S., Weisz, K., Chen, Z., Uhler, M. D., Rui, L., Gonzalez, F. J., et al. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.01.004 · Cited by 51
Effects of saxagliptin on β ‐cell stimulation and insulin secretion in patients with type 2 diabetes
Henry, R. R., Smith, S. R., Schwartz, S. L., Mudaliar, S. R., Deacon, C. F., Holst, J. J., Duan, R. Y., Chen, R. S., & List, J. F. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01417.x · Cited by 49
How Should We Think About the Role of the Brain in Glucose Homeostasis and Diabetes?
Deem, J. D., Muta, K., Scarlett, J. M., Morton, G. J., & Schwartz, M. W. (2017) · Diabetes · doi:10.2337/dbi16-0067 · Cited by 49
Selection and characterization of DNA aptamer against glucagon receptor by cell-SELEX
Wang, G., Liu, J., Chen, K., Xu, Y., Liu, B., Liao, J., Zhu, L., Hu, X., Li, J., Pu, Y. D., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-05840-w · Cited by 49
Moritoh, Y., Takeuchi, K., Asakawa, T., Kataoka, O., & Odaka, H. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00145.x · Cited by 49
Novel function of transthyretin in pancreatic alpha cells
Su, Y., Jono, H., Misumi, Y., Senokuchi, T., Guo, J., Ueda, M., Shinriki, S., Tasaki, M., Shono, M., Obayashi, K., et al. (2012) · FEBS Letters · doi:10.1016/j.febslet.2012.10.025 · Cited by 49
The regulation of pre- and post-maturational plasticity of mammalian islet cell mass
Mezza, T., & Kulkarni, R. (2014) · Diabetologia · doi:10.1007/s00125-014-3251-7 · Cited by 48
Spigelman, A. F., Dai, X., & MacDonald, P. E. (2010) · Diabetologia · doi:10.1007/s00125-010-1759-z · Cited by 48
EJE PRIZE 2018: A gut feeling about glucagon
Knop, F. K. (2018) · European Journal of Endocrinology · doi:10.1530/eje-18-0197 · Cited by 47
Vajda, E. G., Logan, D., Lasseter, K., Armas, D., Plotkin, D. J., Pipkin, J., Li, Y.-X., Zhou, R., Klein, D., Wei, X., et al. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12752 · Cited by 48
Park, Y. M., Heden, T. D., Liu, Y., Nyhoff, L. M., Thyfault, J. P., Leidy, H. J., & Kanaley, J. A. (2014) · Journal of Nutrition · doi:10.3945/jn.114.202549 · Cited by 47
Prenatal exposure to bisphenol A alters mouse fetal pancreatic morphology and islet composition
Whitehead, R., Guan, H., Arany, E. J., Cernea, M., & Yang, K. (2016) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci-2015-0052 · Cited by 47
Pleiotropic Actions of the Incretin Hormones
McIntosh, C. H. S., Widenmaier, S. B., & Kim, S. (2010) · Vitamins and hormones · doi:10.1016/b978-0-12-381517-0.00002-3 · Cited by 46
Glucagon and Cyclic AMP: Time to Turn the Page?
L. Rodgers, R. (2012) · Current Diabetes Reviews · doi:10.2174/157339912802083540 · Cited by 42
Choukem, S. P., Sobngwi, E., Boudou, P., Fetita, L.-S., Porcher, R., Ibrahim, F., Blondeau, B., Vexiau, P., Mauvais‐Jarvis, F., Calvo, F. M., et al. (2012) · Diabetes Care · doi:10.2337/dc12-0798 · Cited by 47
Modeling the pancreatic α-cell: dual mechanisms of glucose suppression of glucagon secretion
Watts, M., & Sherman, A. (2014) · Biophysical Journal · doi:10.1016/j.bpj.2013.11.4504 · Cited by 45
Gs-DREADD Knock-In Mice for Tissue-Specific, Temporal Stimulation of Cyclic AMP Signaling
Akhmedov, D., Mendoza‐Rodriguez, M. G., Rajendran, K., Rossi, M., Wess, J., & Berdeaux, R. (2017) · Molecular and Cellular Biology · doi:10.1128/mcb.00584-16 · Cited by 45
Glucagon, from past to present: a century of intensive research and controversies
Scheen, A. J., & Lefèbvre, P. J. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00349-7 · Cited by 44
Kazierad, D. J., Bergman, A., Tan, B., Erion, D. M., Somayaji, V., Lee, D. S., & Rolph, T. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12672 · Cited by 44
Cross Talk Between Insulin and Glucagon Receptor Signaling in the Hepatocyte
Habegger, K. M. (2022) · Diabetes · doi:10.2337/dbi22-0002 · Cited by 44
Tirzepatide: A Promising Drug for Type 2 Diabetes and Beyond
Dutta, P., Kumar, Y., Babu, A. T., Ravindran, S. G., Salam, A., Rai, B., Baskar, A., Dhawan, A., & Jomy, M. (2023) · Cureus · doi:10.7759/cureus.38379 · Cited by 46
Recent progress in the development of small-molecule glucagon receptor antagonists
Sammons, M. F., & Lee, E. C. Y. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.07.092 · Cited by 43
Guzmán-Pérez, A., Pfefferkorn, J. A., Lee, E. C. Y., Stevens, B. D., Aspnes, G. E., Bian, J., Didiuk, M. T., Filipski, K. J., Moore, D., Perreault, C., et al. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.03.014 · Cited by 43
MicroRNA-296: a promising target in the pathogenesis of atherosclerosis?
Li, H., Ouyang, X.-P., Jiang, T., Zheng, X., He, P., & Zhao, G.-J. (2018) · Molecular Medicine · doi:10.1186/s10020-018-0012-y · Cited by 43
Short Chain Fatty Acids, pancreatic dysfunction and type 2 diabetes
Mandaliya, D. K., & Seshadri, S. (2019) · Pancreatology · doi:10.1016/j.pan.2019.04.013 · Cited by 43
Piro, S., Maniscalchi, E. T., Monello, A., Pandini, G., Mascali, L. G., Rabuazzo, A. M., & Purrello, F. (2010) · Endocrinology · doi:10.1210/en.2009-1472 · Cited by 43
Anti-diabesity middle eastern medicinal plants and their action mechanisms
Saad, B., Kmail, A., & Haq, S. Z. H. (2022) · Evidence-Based Complementary and Alternative Medicine · doi:10.1155/2022/2276094 · Cited by 42
Saponaro, C., Gmyr, V., Thévenet, J., Moerman, E., Delalleau, N., Pasquetti, G., Coddeville, A., Quenon, A., Daoudi, M., Hubert, T., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.07.009 · Cited by 36
Basal α-Cell Up-Regulation in Obese Insulin-Resistant Adolescents
Weiss, R., D'Adamo, E., Santoro, N., Hershkop, K., & Caprio, S. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-1275 · Cited by 39
Guardado Mendoza, R., Perego, C., Finzi, G., La Rosa, S., Capella, C., Jimenez-Ceja, L. M., Velloso, L. A., Saad, M. J. A., Sessa, F., Bertuzzi, F., et al. (2015) · Diabetologia · doi:10.1007/s00125-015-3625-5 · Cited by 41
“However, studies of islet cell composition in humans have the following limitations: (1) they are necessarily performed on autoptic pancreases obtained 48–72 h post mortem when autolysis causes cell damage; (2) the vast majority of studies have compared non-diabetic vs diabetic subjects and have not examined islet com…”
Clinical Approaches to Preserve β-Cell Function in Diabetes
WAJCHENBERG, B. L. (2010) · Advances in experimental medicine and biology · doi:10.1007/978-90-481-3271-3_23 · Cited by 41
Henquin, J.-C., Ibrahim, M. M., & Rahier, J. (2017) · Scientific Reports · doi:10.1038/s41598-017-10296-z · Cited by 40
Kazda, C. M., Frias, J., Foga, I., Cui, X., Guzman, C. B., Garhyan, P., Heilmann, C., Yang, J. A., & Hardy, T. A. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12904 · Cited by 39
Prediabetes diagnosis criteria, type 2 diabetes risk and dietary modulation: The CORDIOPREV study
Roncero‐Ramos, I., Alcala-Diaz, J. F., Rangel-Zúñiga, O. A., Gómez-Delgado, F., Jiménez-Lucena, R., García‐Ríos, A., Vals‐Delgado, C., Romero-Baldonado, C., Luque, R. M., Ordovás, J. M., et al. (2019) · Clinical Nutrition · doi:10.1016/j.clnu.2019.02.027 · Cited by 39
Impaired Glucose-Induced Glucagon Suppression after Partial Pancreatectomy
Schrader, H., Menge, B. A., Breuer, T. G. K., Ritter, P. R., Uhl, W. H., Schmidt, W. E., Holst, J. J., & Meier, J. J. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0826 · Cited by 39
Ottosson-Laakso, E., Tuomilehto, J., Forsén, B., Gullström, M., Groop, P., Groop, L., & Vikman, P. J. (2016) · PLoS ONE · doi:10.1371/journal.pone.0146114 · Cited by 39
A central role for hypoxia-inducible factor (HIF)-2α in hepatic glucose homeostasis
Ramakrishnan, S. K., & Shah, Y. M. (2017) · Nutrition and Healthy Aging · doi:10.3233/nha-170022 · Cited by 39
Merino, B., Alonso‐Magdalena, P., Lluesma, M., Ñeco, P., González, A., Marroquí, L., García‐Arévalo, M., Nadal, Á., & Quesada, I. (2015) · Scientific Reports · doi:10.1038/srep11622 · Cited by 38
Glucagon, cyclic AMP, and hepatic glucose mobilization: A half‐century of uncertainty
Rodgers, R. L. (2022) · Physiological Reports · doi:10.14814/phy2.15263 · Cited by 38
Gjesing, A. P., Kjems, L., Vestmar, M. A., Grarup, N., Linneberg, A. R., Deacon, C. F., Holst, J. J., Pedersen, O. B., & Hansen, T. F. (2010) · Diabetologia · doi:10.1007/s00125-010-1940-4 · Cited by 38
Reversal of angiotensin ll-induced β-cell dedifferentiation via inhibition of NF-κb signaling
Chen, H., Zhou, W., Ruan, Y., Yang, L., Xu, N., Chen, R., Yang, R., Sun, J. M., & Zhang, Z. (2018) · Molecular Medicine · doi:10.1186/s10020-018-0044-3 · Cited by 37
Casu, A., Echeverri, G. J., Bottino, R., van der Windt, D. J., He, J., Ekser, B., Ball, S. F., Ayares, D., & Cooper, D. K. C. (2010) · Xenotransplantation · doi:10.1111/j.1399-3089.2010.00572.x · Cited by 37
Inaba, W., Mizukami, H., Kamata, K., Takahashi, K., Tsuboi, K., & Yagihashi, S. (2012) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2012.07.030 · Cited by 36
Song, G., Pacini, G., Ahrén, B., & D’Argenio, D. Z. (2017) · Peptides · doi:10.1016/j.peptides.2016.12.012 · Cited by 33
Demant, M., Bagger, J. I., Suppli, M. P., Lund, A., Gyldenløve, M., Hansen, K. B., Hare, K. J., Christensen, M., Sonne, D. P., Holst, J. J., et al. (2018) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2018.0066 · Cited by 38
Guardado‐Mendoza, R., Salazar-López, S. S., Alvarez-Canales, M. F. D. L. L., Farfán-Vázquez, D., Martínez-López, Y. E., Jiménez-Ceja, L. M., Suárez-Pérez, E. L., Angulo-Romero, F., Evia-Viscarra, M. L., de Oca-Loyola, M. L. M., et al. (2019) · Metabolism · doi:10.1016/j.metabol.2019.154054 · Cited by 36
GIP’s involvement in the pathophysiology of type 2 diabetes
Christensen, M. B., Gasbjerg, L. S., Heimbürger, S. M., Stensen, S., Vilsbøll, T., & Knop, F. K. (2020) · Peptides · doi:10.1016/j.peptides.2019.170178 · Cited by 35
Glucagon in type 2 diabetes: Friend or foe?
Caruso, I., Marrano, N., Biondi, G., Genchi, V. A., D'Oria, R., Sorice, G. P., Perrini, S., Cignarelli, A., Natalicchio, A., Laviola, L., et al. (2023) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3609 · Cited by 35
Li, Z., Zhang, Y., Quan, X., Yang, Z., Zeng, X., Ji, L., Sun, F., & Zhan, S. (2016) · PLOS ONE · doi:10.1371/journal.pone.0154206 · Cited by 33
Pettus, J., D’Alessio, D. A., Frías, J. P., Vajda, E. G., Pipkin, J. D., Rosenstock, J., Williamson, G., Zangmeister, M. A., Zhi, L., & Marschke, K. B. (2019) · Diabetes Care · doi:10.2337/dc19-1328 · Cited by 35
Liu, T., Ji, R.-L., & Tao, Y.-X. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.108044 · Cited by 34
Winzell, M. S., Coghlan, M. P., Leighton, B., Frangioudakis, G., Smith, D. M., Storlien, L. H., & Åhrén, B. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.05.009 · Cited by 34
Leptin downregulates expression of the gene encoding glucagon in alphaTC1-9 cells and mouse islets
Marroquí, L., Vieira, E. C., González, A., Nadal, Á., & Quesada, I. (2011) · Diabetologia · doi:10.1007/s00125-010-2024-1 · Cited by 34
Li, B., Guo, J., Xi, Z., Xu, J., Zuo, Z., & Wang, C. (2017) · Archives of Toxicology · doi:10.1007/s00204-017-1961-6 · Cited by 34
Grg3/TLE3 and Grg1/TLE1 Induce Monohormonal Pancreatic β-Cells While Repressing α-Cell Functions
Metzger, D. E., Liu, C., Ziaie, A. S., Naji, A., & Zaret, K. S. (2014) · Diabetes · doi:10.2337/db13-0867 · Cited by 33
SREBP1c-PAX4 Axis Mediates Pancreatic β-Cell Compensatory Responses Upon Metabolic Stress
Lee, G., Jang, H., Kim, Y. Y., Choe, S. S., Kong, J., Hwang, I., Park, J., Im, S., & Kim, J. B. (2018) · Diabetes · doi:10.2337/db18-0556 · Cited by 32
Inhibition of PHLPP1/2 phosphatases rescues pancreatic β-cells in diabetes
Lupše, B., Annamalai, K., Ibrahim, H., Kaur, S., Geravandi, S., Sarma, B., Pal, A., Awal, S., Joshi, A., Rafizadeh, S., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109490 · Cited by 32
Lundqvist, M., Almby, K. E., Wiklund, U., Abrahamsson, N., Kamble, P. G., Pereira, M. J., & Eriksson, J. W. (2020) · Diabetologia · doi:10.1007/s00125-020-05332-z · Cited by 31
Alba, M., Åhrén, B., Inzucchi, S. E., Guan, Y., Mallick, M., Xu, L., O’Neill, E. A., Williams‐Herman, D., Kaufman, K. D., & Goldstein, B. J. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12145 · Cited by 30
α-cell electrophysiology and the regulation of glucagon secretion
Gao, R., Acreman, S., Ma, J., Abdulkader, F., Wendt, A., & Zhang, Q. (2023) · Journal of Endocrinology · doi:10.1530/joe-22-0295 · Cited by 29
Sloan, J. H., Siegel, R. W., Ivanova-Cox, Y. T., Watson, D. E., Deeg, M. A., & Konrad, R. J. (2012) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2012.07.111 · Cited by 29
A Narrative Review of Potential Future Antidiabetic Drugs: Should We Expect More?
Chikara, G., Sharma, P. K., Dwivedi, P., Charan, J., Ambwani, S. R., & Singh, S. (2017) · Indian Journal of Clinical Biochemistry · doi:10.1007/s12291-017-0668-z · Cited by 29
Kazierad, D. J., Chidsey, K., Somayaji, V. R., Bergman, A. J., & Calle, R. A. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13440 · Cited by 30
High-fat diet impacts more changes in beta-cell compared to alpha-cell transcriptome
Dusaulcy, R., Handgraaf, S., Visentin, F., Howald, C., Dermitzakis, E. T., Philippé, J., & Gosmain, Y. (2019) · PLoS ONE · doi:10.1371/journal.pone.0213299 · Cited by 29
Guardado‐Mendoza, R., Jiménez-Ceja, L. M., Majluf‐Cruz, A., Kamath, S., Fiorentino, T. V., Casiraghi, F., Velazquez, A. O. C., DeFronzo, R. A., Dick, E. J., Davalli, A. M., et al. (2012) · International Journal of Obesity · doi:10.1038/ijo.2012.205 · Cited by 28
Doiron, B., Hu, W., Norton, L., & DeFronzo, R. A. (2012) · Diabetologia · doi:10.1007/s00125-011-2414-z · Cited by 28
Morettini, M., Burattini, L., Göbl, C., Pacini, G., Ahrén, B., & Tura, A. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.611147 · Cited by 27
“Indeed, in patients with T2DM elevated plasma glucagon levels have been observed in the fasting state, and defective suppression of glucagon secretion exists in the postprandial state, resulting in elevated plasma glucagon levels (7), which have been shown to reflect an altered insulin inhibition of alpha-cell glucago…”
BackgroundPillai, S. S., & Mini, S. (2015) · Journal of Functional Foods · doi:10.1016/j.jff.2015.10.007 · Cited by 27
Bashier, A. M., Hussain, A. A. B., Abdelgadir, E., Eltinay, A. T., Thadani, P., Abdalla, M. E., Abusnana, S., & Alawadi, F. (2015) · Journal of Diabetes & Metabolic Disorders · doi:10.1186/s40200-015-0178-6 · Cited by 26
Fang, L., Guo, J., Wang, Q., Ou, K., Zou, M., Lv, L., Chen, M., & Wang, C. (2020) · Environmental Science & Technology · doi:10.1021/acs.est.0c04171 · Cited by 26
Aziz, K. M. A. (2015) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s54683 · Cited by 26
Bergman, A. J., Tan, B., Somayaji, V. R., Calle, R. A., & Kazierad, D. J. (2017) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.01.019 · Cited by 26
Incretin and Glucagon Levels in Adult Offspring Exposed to Maternal Diabetes in Pregnancy
Kelstrup, L., Clausen, T. D., Mathiesen, E. R., Hansen, T. F., Holst, J. J., & Damm, P. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3978 · Cited by 26
Shanmuga, S. C., & Subramanian, S. P. (2012) · Asian Pacific Journal of Tropical Biomedicine · doi:10.1016/s2221-1691(12)60444-4 · Cited by 25
Pathophysiology of type 2 diabetes mellitus
Yki‐Järvinen, H. (2011) · doi:10.1093/med/9780199235292.003.1336 · Cited by 25
Matsumoto, S., Yamazaki, M., Kadono, M., Iwase, H., Kobayashi, K., Okada, H., Fukui, M., Hasegawa, G., & Nakamura, N. (2013) · Journal of Clinical Biochemistry and Nutrition · doi:10.3164/jcbn.13-14 · Cited by 25
Pérez, Á., Rojas, P., Carrasco, F., Basfi-fer, K., Pérez‐Bravo, F., Codoceo, J., Inostroza, J., Galgani, J. E., Gilmore, L. A., & Ruz, M. (2018) · Journal of Trace Elements in Medicine and Biology · doi:10.1016/j.jtemb.2018.03.019 · Cited by 26
Solanum anguivi Lam. Fruits: Their Potential Effects on Type 2 Diabetes Mellitus
Nakitto, A. M. S., Muyonga, J. H., Byaruhanga, Y. B., & Wagner, A. E. (2021) · Molecules · doi:10.3390/molecules26072044 · Cited by 25
Christensen, M., Knop, F. K., Vilsbøll, T., Aaboe, K., Holst, J. J., Madsbad, S., & Krarup, T. (2010) · Regulatory Peptides · doi:10.1016/j.regpep.2010.05.004 · Cited by 25
Proton pump inhibitors: impact on glucose metabolism
Boj-Carceller, D. (2012) · Endocrine · doi:10.1007/s12020-012-9755-3 · Cited by 25
Postprandial Dysmetabolism and the Heart
Garber, A. J. (2012) · Heart Failure Clinics · doi:10.1016/j.hfc.2012.06.004 · Cited by 24
Ikeda, K., Fujimoto, S., Goto, M., Yamada, C., Hamasaki, A., Shide, K., Kawamura, T., & Inagaki, N. (2011) · American Journal of Clinical Nutrition · doi:10.3945/ajcn.111.017889 · Cited by 24
Dusaulcy, R., Handgraaf, S., Heddad-Masson, M., Visentin, F., Vesin, C., Reimann, F., Gribble, F. M., Philippé, J., & Gosmain, Y. (2015) · Endocrinology · doi:10.1210/en.2015-1725 · Cited by 25
Gap junction coupling and islet delta-cell function in health and disease
MIRANDA, C. A., Samad, M., Vergari, E., & Briant, L. J. B. (2021) · Peptides · doi:10.1016/j.peptides.2021.170704 · Cited by 23
Zhang, Z., Liu, C., Gan, Z., Wang, X., Yi, Q., Liu, Y., Wang, Y., Lu, B., Du, H., Shao, J., et al. (2013) · International Journal of Endocrinology · doi:10.1155/2013/319586 · Cited by 23
Wang, L., Luk, C. T., Cai, E. P., Schroer, S. A., Allister, E. M., Shi, S. Y., Wheeler, M. B., Gaisano, H. Y., & Woo, M. (2014) · Diabetes · doi:10.2337/db13-1715 · Cited by 23
Beglinger, S., Meyer‐Gerspach, A. C., Graf, S., Zumsteg, U., Drewe, J., Beglinger, C., & Gutzwiller, J. (2014) · Obesity · doi:10.1002/oby.20805 · Cited by 23
Feigh, M., Andreassen, K. V., Neutzsky-Wulff, A. V., Petersen, S., Hansen, C., Bay‐Jensen, A., Henriksen, J. E., Beck‐Nielsen, H., Christiansen, C., Henriksen, K., et al. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.01979.x · Cited by 23
Glucagon and hyperglycaemia in diabetes
Cryer, P. E. (2008) · Clinical Science · doi:10.1042/cs20070434 · Cited by 21
The Insulin Receptor Talks to Glucagon?
Gromada, J., Duttaroy, A., & Rorsman, P. (2009) · Cell Metabolism · doi:10.1016/j.cmet.2009.03.008 · Cited by 22
de Heer, J., & Göke, B. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2014.955013 · Cited by 21
Lu, K., Chen, S., Lin, Y., Wu, H., & Chao, P. (2020) · Food Science & Nutrition · doi:10.1002/fsn3.1966 · Cited by 21
Glycoprotein 130 Receptor Signaling Mediates α-Cell Dysfunction in a Rodent Model of Type 2 Diabetes
Chow, S., Speck, M., Yoganathan, P., Nąckiewicz, D., Hansen, A. M. K., Ladefoged, M., Rabe, B., Rose‐John, S., Voshol, P. J., Lynn, F. C., et al. (2014) · Diabetes · doi:10.2337/db13-1121 · Cited by 21
Metadata
- Authors
- Dunning, B. E., & Gerich, J. E.
- Affiliations
- PharmaWrite, Princeton, New Jersey 08540
- University of Rochester Medicine (US)
- Corresponding author
- Gerich, John E.
- Venue
- Endocrine Reviews
- Publisher
- The Endocrine Society
- Published
- 2007-04-04
- Volume
- 28
- Issue
- 3
- Pages
- 253-283
- ISSN
- 0163-769X (ISSN-L)
- 1945-7189
- OpenAlex
- W2088987697
- Cited by
- 369
- References
- 323
- Citations by year
- 2026: 6 · 2025: 7 · 2024: 16 · 2023: 17 · 2022: 14 · 2021: 20 · 2020: 15 · 2019: 21 · 2018: 17 · 2017: 24 · 2016: 25 · 2015: 23 · 2014: 24 · 2013: 27 · 2012: 27
- FWCI
- 2.77
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Endocrine Reviews (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Bristol-Myers Squibb
- Pfizer
- GlaxoSmithKline
- Sanofi
- University of Rochester
- Kowa Company
- Eisai
- Novo Nordisk
- Medical Center, University of Rochester
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- glucagon, alpha cells, type 2 diabetes, fasting hyperglycemia, postprandial hyperglycemia, hyperglucagonemia, glucagon receptor antagonists, somatostatin, GLP-1 receptor agonists, DPP-4 inhibitors, glucagon secretion, glycemic control, glucoregulation
- MeSH terms
- Animals, Diabetes Mellitus, Type 2, Fasting, Glucagon, Humans, Hyperglycemia, Receptors, Glucagon, Postprandial Period, Glucagon-Secreting Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.